Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > OT:Cancer Radiopharmaceutical Therapy reports Adverse Events
View:
Post by Noteable on May 26, 2024 8:49am

OT:Cancer Radiopharmaceutical Therapy reports Adverse Events

May 24, 1014 - J&J reports 4 patient deaths in early stage prostate cancer. Four patients died in Johnson & Johnson's Phase I study for its investigational targeted radiopharmaceutical candidate JNJ-6420 in metastatic castration-resistant prostate cancer, according to a readout released Thursday, ahead of next week's ASCO 2024 annual meeting. 

Thursday’s data come from 57 patients who had received at least one dose of JNJ-6420, of whom 31 stayed on treatment for 24 weeks or longer. 

However, in terms of safety, J&J’s investigational radiotherapy appears to be fairly toxic. More than 60% of patients developed treatment-emergent adverse events (TEAE) that were at least grade 3 in severity, while almost 37% had a serious TEAE.Common adverse events included anemia, low platelet count and abnormal reductions in white blood cells. 

Nine patients dropped out of the study due to severe side effects that were deemed related to the study drug.

 
https://www.biospace.com/article/asco24-j-and-j-reports-four-patient-deaths-in-early-stage-radiotherapy-prostate-cancer-trial/
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities